These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38702859)

  • 21. Disentangling estimands and the intention-to-treat principle.
    Leuchs AK; Brandt A; Zinserling J; Benda N
    Pharm Stat; 2017 Jan; 16(1):12-19. PubMed ID: 27910217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimands in published protocols of randomised trials: urgent improvement needed.
    Kahan BC; Morris TP; White IR; Carpenter J; Cro S
    Trials; 2021 Oct; 22(1):686. PubMed ID: 34627347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Special issue PRO] A demonstration of estimands and sensitivity analyses for time-to-deterioration of patient reported outcomes.
    Floden L; DeRosa M; Roydhouse J; Beaumont JL; Hudgens S
    J Biopharm Stat; 2024 Apr; ():1-15. PubMed ID: 38686622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. If you can't comply with dialysis, how do you expect me to trust you with transplantation? Australian nephrologists' views on indigenous Australians' 'non-compliance' and their suitability for kidney transplantation.
    Anderson K; Devitt J; Cunningham J; Preece C; Jardine M; Cass A
    Int J Equity Health; 2012 Apr; 11():21. PubMed ID: 22513223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimands in practice: Bridging the gap between study objectives and statistical analysis.
    Phillips A; Clark T
    Pharm Stat; 2021 Jan; 20(1):68-76. PubMed ID: 32893473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Principles and recommendations for incorporating estimands into clinical study protocol templates.
    Lynggaard H; Bell J; Lösch C; Besseghir A; Rantell K; Schoder V; Lanius V
    Trials; 2022 Aug; 23(1):685. PubMed ID: 35986349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The issue is not 'compliance': exploring exposure to malaria vector bites through social dynamics in Burkina Faso.
    Guglielmo F; Ranson H; Sagnon N; Jones C
    Anthropol Med; 2021 Dec; 28(4):508-525. PubMed ID: 33970705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The detailed clinical objectives approach to designing clinical trials and choosing estimands.
    Bell J; Hamilton A; Sailer O; Voss F
    Pharm Stat; 2021 Nov; 20(6):1112-1124. PubMed ID: 34013553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding estimands.
    Gogtay NJ; Ranganathan P; Aggarwal R
    Perspect Clin Res; 2021; 12(2):106-112. PubMed ID: 34012908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A structured approach to choosing estimands and estimators in longitudinal clinical trials.
    Mallinckrodt CH; Lin Q; Lipkovich I; Molenberghs G
    Pharm Stat; 2012; 11(6):456-61. PubMed ID: 22962024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple definitions of 'compliance'.
    Lehmann ED; Hopkins KD; Gosling RG
    Clin Sci (Lond); 1996 May; 90(5):433-4. PubMed ID: 8665782
    [No Abstract]   [Full Text] [Related]  

  • 32. Patient 'non-compliance' and 'missing data' in quality of life research: where does the problem lie?
    Moynihan C
    Eur J Cancer; 1998 Jan; 34(1):9-11. PubMed ID: 9624232
    [No Abstract]   [Full Text] [Related]  

  • 33. Estimands: bringing clarity and focus to research questions in clinical trials.
    Clark TP; Kahan BC; Phillips A; White I; Carpenter JR
    BMJ Open; 2022 Jan; 12(1):e052953. PubMed ID: 34980616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies.
    Unkel S; Amiri M; Benda N; Beyersmann J; Knoerzer D; Kupas K; Langer F; Leverkus F; Loos A; Ose C; Proctor T; Schmoor C; Schwenke C; Skipka G; Unnebrink K; Voss F; Friede T
    Pharm Stat; 2019 Mar; 18(2):166-183. PubMed ID: 30458579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adherence, per-protocol effects, and the estimands framework.
    Keene O
    Pharm Stat; 2023; 22(6):1141-1144. PubMed ID: 37477077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 'Compliance' to exercise: how much is really needed for a healthy heart (and mind)?
    DeConne TM; Stock JM; Migdal KU
    J Physiol; 2018 Oct; 596(20):4817-4818. PubMed ID: 30169903
    [No Abstract]   [Full Text] [Related]  

  • 37. Current Practices in Choosing Estimands and Sensitivity Analyses in Clinical Trials: Results of the ICH E9 Survey.
    Fletcher C; Tsuchiya S; Mehrotra DV
    Ther Innov Regul Sci; 2017 Jan; 51(1):69-76. PubMed ID: 30236003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Translating questions to estimands in randomized clinical trials with intercurrent events.
    Stensrud MJ; Dukes O
    Stat Med; 2022 Jul; 41(16):3211-3228. PubMed ID: 35578779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incorporating estimands into clinical trial statistical analysis plans.
    Kang M; Kendall MA; Ribaudo H; Tierney C; Zheng L; Smeaton L; Lindsey JC
    Clin Trials; 2022 Jun; 19(3):285-291. PubMed ID: 35257600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Causal inference with recurrent and competing events.
    Janvin M; Young JG; Ryalen PC; Stensrud MJ
    Lifetime Data Anal; 2024 Jan; 30(1):59-118. PubMed ID: 37173588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.